Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection

literature review and risk analysis

Giovanni Galati, Moises Muley, Mauro Viganò, Massimo Iavarone, Alessandro Vitale, Chiara Dell’Unto, Quirino Lai, Giuseppe Cabibbo, Rodolfo Sacco, Erica Villa, Franco Trevisani

Research output: Contribution to journalReview article

Abstract

Introduction: Concerns were raised about a high occurrence of hepatocellular carcinoma (HCC) after successful treatment of chronic hepatitis C (CHC) by direct-acting antivirals (DAAs). Areas covered: The authors summarize the clinical studies reporting the occurrence rate and risk factors of HCC after DAAs in CHC. Expert opinion: The recent introduction of all-oral DAAs has substantially changed the scenario of CHC, achieving a sustained virological response (SVR) in >90% of cases. Earlier concerns raised about an increasing incidence of HCC post-DAAs were flawed by large heterogeneity of patients, the limited number of well-designed prospective studies (only nine, up to date) and the inclusion of a large number of patients with advanced liver disease, previously excluded from interferon-based studies. Current data on DAAs have shown a lower risk of HCC development; however, they were unable to identify patients at greater risk for HCC occurrence after SVR. Surveillance strategy, likely lifelong, is mandatory in these patients according to general expert opinion.

Original languageEnglish
Pages (from-to)603-610
Number of pages8
JournalExpert Opinion on Drug Safety
Volume18
Issue number7
DOIs
Publication statusPublished - Jul 3 2019

Fingerprint

Virus Diseases
Hepacivirus
Antiviral Agents
Hepatocellular Carcinoma
Chronic Hepatitis C
Expert Testimony
Therapeutics
Interferons
Liver Diseases
Prospective Studies
Incidence

Keywords

  • DAA/direct-acting antivirals
  • HCC
  • HCV
  • Hepatocellular carcinoma
  • occurrence

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection : literature review and risk analysis. / Galati, Giovanni; Muley, Moises; Viganò, Mauro; Iavarone, Massimo; Vitale, Alessandro; Dell’Unto, Chiara; Lai, Quirino; Cabibbo, Giuseppe; Sacco, Rodolfo; Villa, Erica; Trevisani, Franco.

In: Expert Opinion on Drug Safety, Vol. 18, No. 7, 03.07.2019, p. 603-610.

Research output: Contribution to journalReview article

Galati, G, Muley, M, Viganò, M, Iavarone, M, Vitale, A, Dell’Unto, C, Lai, Q, Cabibbo, G, Sacco, R, Villa, E & Trevisani, F 2019, 'Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis', Expert Opinion on Drug Safety, vol. 18, no. 7, pp. 603-610. https://doi.org/10.1080/14740338.2019.1617272
Galati, Giovanni ; Muley, Moises ; Viganò, Mauro ; Iavarone, Massimo ; Vitale, Alessandro ; Dell’Unto, Chiara ; Lai, Quirino ; Cabibbo, Giuseppe ; Sacco, Rodolfo ; Villa, Erica ; Trevisani, Franco. / Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection : literature review and risk analysis. In: Expert Opinion on Drug Safety. 2019 ; Vol. 18, No. 7. pp. 603-610.
@article{c48fdafb61eb4170b1b71fdb522210e5,
title = "Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis",
abstract = "Introduction: Concerns were raised about a high occurrence of hepatocellular carcinoma (HCC) after successful treatment of chronic hepatitis C (CHC) by direct-acting antivirals (DAAs). Areas covered: The authors summarize the clinical studies reporting the occurrence rate and risk factors of HCC after DAAs in CHC. Expert opinion: The recent introduction of all-oral DAAs has substantially changed the scenario of CHC, achieving a sustained virological response (SVR) in >90{\%} of cases. Earlier concerns raised about an increasing incidence of HCC post-DAAs were flawed by large heterogeneity of patients, the limited number of well-designed prospective studies (only nine, up to date) and the inclusion of a large number of patients with advanced liver disease, previously excluded from interferon-based studies. Current data on DAAs have shown a lower risk of HCC development; however, they were unable to identify patients at greater risk for HCC occurrence after SVR. Surveillance strategy, likely lifelong, is mandatory in these patients according to general expert opinion.",
keywords = "DAA/direct-acting antivirals, HCC, HCV, Hepatocellular carcinoma, occurrence",
author = "Giovanni Galati and Moises Muley and Mauro Vigan{\`o} and Massimo Iavarone and Alessandro Vitale and Chiara Dell’Unto and Quirino Lai and Giuseppe Cabibbo and Rodolfo Sacco and Erica Villa and Franco Trevisani",
year = "2019",
month = "7",
day = "3",
doi = "10.1080/14740338.2019.1617272",
language = "English",
volume = "18",
pages = "603--610",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection

T2 - literature review and risk analysis

AU - Galati, Giovanni

AU - Muley, Moises

AU - Viganò, Mauro

AU - Iavarone, Massimo

AU - Vitale, Alessandro

AU - Dell’Unto, Chiara

AU - Lai, Quirino

AU - Cabibbo, Giuseppe

AU - Sacco, Rodolfo

AU - Villa, Erica

AU - Trevisani, Franco

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Introduction: Concerns were raised about a high occurrence of hepatocellular carcinoma (HCC) after successful treatment of chronic hepatitis C (CHC) by direct-acting antivirals (DAAs). Areas covered: The authors summarize the clinical studies reporting the occurrence rate and risk factors of HCC after DAAs in CHC. Expert opinion: The recent introduction of all-oral DAAs has substantially changed the scenario of CHC, achieving a sustained virological response (SVR) in >90% of cases. Earlier concerns raised about an increasing incidence of HCC post-DAAs were flawed by large heterogeneity of patients, the limited number of well-designed prospective studies (only nine, up to date) and the inclusion of a large number of patients with advanced liver disease, previously excluded from interferon-based studies. Current data on DAAs have shown a lower risk of HCC development; however, they were unable to identify patients at greater risk for HCC occurrence after SVR. Surveillance strategy, likely lifelong, is mandatory in these patients according to general expert opinion.

AB - Introduction: Concerns were raised about a high occurrence of hepatocellular carcinoma (HCC) after successful treatment of chronic hepatitis C (CHC) by direct-acting antivirals (DAAs). Areas covered: The authors summarize the clinical studies reporting the occurrence rate and risk factors of HCC after DAAs in CHC. Expert opinion: The recent introduction of all-oral DAAs has substantially changed the scenario of CHC, achieving a sustained virological response (SVR) in >90% of cases. Earlier concerns raised about an increasing incidence of HCC post-DAAs were flawed by large heterogeneity of patients, the limited number of well-designed prospective studies (only nine, up to date) and the inclusion of a large number of patients with advanced liver disease, previously excluded from interferon-based studies. Current data on DAAs have shown a lower risk of HCC development; however, they were unable to identify patients at greater risk for HCC occurrence after SVR. Surveillance strategy, likely lifelong, is mandatory in these patients according to general expert opinion.

KW - DAA/direct-acting antivirals

KW - HCC

KW - HCV

KW - Hepatocellular carcinoma

KW - occurrence

UR - http://www.scopus.com/inward/record.url?scp=85067605582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067605582&partnerID=8YFLogxK

U2 - 10.1080/14740338.2019.1617272

DO - 10.1080/14740338.2019.1617272

M3 - Review article

VL - 18

SP - 603

EP - 610

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 7

ER -